|
**Overview**: Cryoglobulins Panel**Introduction**: The Cryoglobulins Panel is a diagnostic tool designed to screen for cryoglobulinemia using serum samples. In India, cryoglobulinemia (types I-III) is associated with hepatitis C (common in northern states), autoimmune diseases (SLE, Sjogren's), and lymphoproliferative disorders, presenting with purpura, arthralgia, neuropathy, renal involvement. High morbidity from underdiagnosis in rural areas, limited immunology labs, delayed rituximab or antiviral therapy leading to vasculitis or renal failure. Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for qualitative detection and typing over 1-2 days with high specificity (requires warm collection/transport), valuable for confirming cryoglobulin-related disease. This diagnostic falls under autoimmune screening and targets patients with palpable purpura, weakness, or HCV, addressing accurate detection to guide immunosuppression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing organ damage. Its serum-based approach ensures reliable detection.**Other Names**: Cryoglobulins Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Cryoglobulin typing standard; in India, linked to HCV screening.**Purpose**: The test screens for 2 parameters including cryoglobulins qualitative to guide cryoglobulinemia diagnosis, type disease, inform therapy.**Test Parameters**: 1. Cryoglobulins Qualitative, 2. Cryoglobulins Type.**Pretest Condition**: No fasting required; patients should report purpura, joint pain, weakness, or HCV history.**Specimen**: 3 mL serum in 1 SST (warm collection/transport critical), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on rash, neuropathy, renal issues, HCV exposure, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated cryoglobulinemia including vasculitis or renal failure, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure warm handling, avoid precipitation, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, cold exposure during collection, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive cryoglobulins indicate cryoglobulinemia, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists or hepatologists should be consulted for management.**Additional Supporting Tests**: HCV RNA, complement levels for confirmation.**Test Limitations**: Requires strict warm handling; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Cryoglobulinemia Studies India 2023. |
